Kulkarni and Afshar-Kharghan Kroshus TJ, Rollins SA, Dalmasso AP, et al. 1995. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation, 60:1194–202. Kroshus TJ, Salerno CT, Yeh CG, et al. 2000. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation. Transplantation, 69:2282–9. Laine M, Jarva H, Seitsonen S, et al. 2007. Y402H polymorphism of complement factor H affects binding afﬁnity to C-reactive protein. J Immunol, 178:3831–6. Laine P, Pentikäinen MO, Würzner R, et al. 2002. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol, 90:404–8. Langlois PF, Gawryl MS. 1988. Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis, 70:95–105. Lazar HL, Bao Y, Gaudiani J, et al. 1999. Total complement inhibition: an effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass. Circulation, 100:1438–42. Lazar HL, Bokesch PM, van Lenta F, et al. 2004. Soluble human complement receptor 1 limits ischemic damage and cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation, 110(11 Suppl 1):II274–9. Lazar HL, Keilani T, Fitzgerald CA, et al. 2007. Beneﬁcial effects of comple- ment inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation, 116(Suppl 11):183–8. Li M, Atmaca-Sonmez P, Othman M, et al. 2006. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet, 38:1049–54. Lin F, Salant DJ, Meyerson H, et al. 2004. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol, 172:2636–42. Mahaffey KW, Granger CB, Nicolau JC, et al. 2003. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to ﬁbrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation, 108:1176–83. Mahaffey KW, Van de Werf F, Shernan SK, et al. 2006. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. Am Heart J, 152:291–6. Maillard JL; Zarco RM. 1968. Decomplementization by a factor extracted from cobra venom. Effect on several immune reactions of the guinea pig and rat. Ann Inst Pasteur Paris, 114:756–74. Maller J, George S, Purcell S, et al. 2006. Common variation in three genes, including a noncoding variant in CFH, strongly inﬂuences risk of age-related macular degeneration. Nat Genet, 38:1055–9. Maroko PR, Carpenter CB, Chiariello M, et al. 1978. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest, 61:661–70. Mathew JP, Shernan SK, White WD, et al. 2004. Preliminary report of the effects of complement suppression with pexelizumab on neurocognitive decline after coronary artery bypass graft surgery. Stroke, 35:2335–9. McManus LM, Kolb WP, Crawford MH, et al. 1983. Complement localiza- tion in ischemic baboon myocardium. Laboratory Invest, 48:436–47. Meuwissen M, van der Wal AC, Niessen HW, et al. 2006. Colocalisation of intraplaque C reactive protein, complement oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol, 59:196–201. Mitchell DA, Pickering MC, Warren J, et al. 2002. C1q deﬁciency and autoimmunity: the effects of genetic background on disease expression. J Immunol, 168:2538–43. Moran P, Beasley H, Gorrell A, et al. 1992. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol, 149:1736–43. 684 Morgan BP, Harris CL. 2003. Complement therapeutics; history and current progress. Mol Immunol, 40:159–70. Moroni G, Trendelenburg M, Del Papa N, et al. 2001. Anti-C1q antibodies may help in diagnosing a renal ﬂare in lupus nephritis. Am J Kidney Dis, 37:490–8. Muller-Eberhard HJ, Fjellstrom KE. 1971. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol, 107:1666–72. Muscari A, Bozzoli C, Puddu GM, et al. 1995. Association of serum C3 levels with the risk of myocardial infarction. Am J Med, 98:357–64. Muscari A, Massarelli G, Bastagli L, et al. 2000. Relationship of serum C3 to fasting insulin, risk factors, and previous ischaemic events in middle-aged men. Eur Heart J, 21:1081–90. Myllymäki J, Saha H, Pasternack A, et al. 2006. High serum C3 predicts poor outcome in IgM nephropathy. Nephron Clin Pract, 102:c122–7. Nijmeijer R, Lagrand WK, Lubbers YT, et al. 2003. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol, 163:269–75. Oksjoki R, Kovanen PT, Meri S, et al. 2007. Function and regulation of the complement system in cardiovascular diseases. Front Biosci, 12:4696–708. Palikhe A, Sinisalo J, Seppänen M, et al. 2007. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol, 99:890–5. Phillips GB. 1970. Studies on a hemolytic factor of cobra venom requiring a heat-labile serum factor. Biochim Biophys Acta, 201:364–74. Pickering MC, Cook HT, Warren J, et al. 2002. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deﬁcient in complement factor H. Nat Genet, 31:424–8. Pickering MC, Warren J, Rose KL, et al. 2006. Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deﬁcient mice. Proc Natl Acad Sci U S A, 103:9649–54. Pinckard RN, O’Rourke RA, Crawford MH, et al. 1980. Complement localization and mediation of ischemic injury in baboon myocardium. J Clin Invest, 66:1050–6. Pugsley MK. 2001. Etanercept. Immunex. Curr Opin Investig Drugs, 2:1725–31. Qin X, Gao B. 2006. The complement system in liver diseases. Cell Mol Immunol, 3:333–40. Ravirajan CT, Wang Y, Matis LA, et al. 2004. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology (Oxford ), 43:442–7. Richards SJ, Hill A, Hillmen P. 2007. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom, 72:291–8. Riedemann NC, Guo RF, Neff TA, et al. 2002. Increased C5a receptor expression in sepsis. J Clin Invest, 110:101–8. Riley RD, Sato H, Zhao ZQ, et al. 2000. Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization. J Thorac Cardiovasc Surg, 120:350–8. Roos A, Nauta AJ, Broers D, et al. 2001. Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol, 167:7052–9. Sahu A, Kay BK, Lambris JD. 1996. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol, 157:884–91. Schwertz R, Rother U, Anders D, et al. 2001. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol, 12:166–72. Seelen MA, Trouw LA, Daha MR. 2003. Diagnostic and prognostic signiﬁcance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens, 12:619–24. Seifert PS, Hansson GK. 1989a. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis, 9:802–11. Seifert PS, Hansson GK. 1989b. Decay accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions. J Clin Invest, 84:597–604. Biologics:Targets & Therapy 2008:2(4)